{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:19:08Z","timestamp":1779333548978,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jdin.2024.03.013","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T16:03:22Z","timestamp":1712073802000},"page":"18-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["International time trends and differences in topical actinic keratosis therapy utilization"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4116-9211","authenticated-orcid":false,"given":"Heather J.","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Ushcatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen Y.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick J.","family":"Levell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Von Schuckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron M.","family":"Drucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jdin.2024.03.013_bib1","first-page":"1099","article-title":"The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma","volume":"33","author":"Fuchs","year":"2007","journal-title":"Dermatol Surg"},{"issue":"1 Pt 2","key":"10.1016\/j.jdin.2024.03.013_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2000.103339","article-title":"The risk of progression to invasive disease","volume":"42","author":"Glogau","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2024.03.013_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jdin.2020.10.013","article-title":"The global burden of skin cancer: a longitudinal analysis from the Global Burden of Disease Study, 1990-2017","volume":"2","author":"Urban","year":"2021","journal-title":"JAAD Int"},{"issue":"6","key":"10.1016\/j.jdin.2024.03.013_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/00019053-200927060-00002","article-title":"Pharmacoeconomic considerations in treating actinic keratosis","volume":"27","author":"Neidecker","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jdin.2024.03.013_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s13555-014-0049-y","article-title":"Actinic keratosis: rationale and management","volume":"4","author":"Dodds","year":"2014","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jdin.2024.03.013_bib6","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.jaad.2021.02.082","article-title":"Guidelines of care for the management of actinic keratosis","volume":"85","author":"Eisen","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2024.03.013_bib7","series-title":"Treatment for Actinic Keratosis","author":"Berman","year":"2023"},{"issue":"1","key":"10.1016\/j.jdin.2024.03.013_bib12","article-title":"Impact of the COVID-19 pandemic on Dermatology practice worldwide: results of a survey promoted by the international dermoscopy society (IDS)","volume":"11","author":"Conforti","year":"2021","journal-title":"Dermatol Pract Concept"},{"issue":"1","key":"10.1016\/j.jdin.2024.03.013_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/1203475420960437","article-title":"Impacts of COVID-19 on dermatologic practice, disease presentation, and immunomodulator prescriptions","volume":"25","author":"Leis","year":"2021","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.jdin.2024.03.013_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2133.1994.tb08544.x","article-title":"Epidemiology of solar keratoses","volume":"131","author":"Frost","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdin.2024.03.013_bib15","first-page":"S26","article-title":"Epidemiology of non-melanoma skin cancer and solar keratoses in Australia: a tale of self-immolation in Elysian fields","volume":"38 Suppl 1","author":"Marks","year":"1997","journal-title":"Australas J Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2024.03.013_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.jdin.2024.03.013_bib17","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/archderm.138.11.1498","article-title":"A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses","volume":"138","author":"Stockfleth","year":"2002","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2024.03.013_bib18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2024.03.013_bib19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jaad.2018.11.024","article-title":"Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: a cohort study","volume":"80","author":"Neugebauer","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2024.03.013_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12822","article-title":"Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: a network meta-analysis","volume":"32","author":"Wu","year":"2019","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jdin.2024.03.013_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-4632.2009.04045.x","article-title":"Effectiveness of 5-fluorouracil treatment for actinic keratosis--a systematic review of randomized controlled trials","volume":"48","author":"Askew","year":"2009","journal-title":"Int J Dermatol"},{"issue":"10","key":"10.1016\/j.jdin.2024.03.013_bib22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized trial of four treatment approaches for actinic keratosis","volume":"380","author":"Jansen","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jdin.2024.03.013_bib23","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/bjd.18884","volume":"183","author":"Jansen","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2024.03.013_bib24","first-page":"40","article-title":"Ingenol mebutate gel (picato): a novel agent for the treatment of actinic keratoses","volume":"39","author":"Fidler","year":"2014","journal-title":"P T"},{"issue":"2","key":"10.1016\/j.jdin.2024.03.013_bib25","first-page":"20","article-title":"United States food and drug administration product label changes","volume":"10","author":"Kircik","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2024.03.013_bib26","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1590\/abd1806-4841.20132083","article-title":"Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5-fluorouracil","volume":"88","author":"Segatto","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2024.03.013_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3315\/jdcr.2015.1199","article-title":"How to treat actinic keratosis? An update","volume":"9","author":"Costa","year":"2015","journal-title":"J Dermatol Case Rep"},{"issue":"6","key":"10.1016\/j.jdin.2024.03.013_bib28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ad.2016.03.004","article-title":"Cost-Effectiveness and cost-utility analysis of ingenol mebutate versus diclofenac 3% and imiquimod 5% in the treatment of actinic keratosis in Spain","volume":"107","author":"El\u00edas","year":"2016","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"10.1016\/j.jdin.2024.03.013_bib29","series-title":"Picato: Withdrawal of the Marketing Authorisation in the European Union","year":"2020"},{"key":"10.1016\/j.jdin.2024.03.013_bib30","series-title":"PICATO (Ingenol Mebutate Gel, 0.015% and 0.05%) - Product Withdrawal in Canada Due to Potential Increased Risk of Skin Cancer","year":"2020"},{"issue":"2","key":"10.1016\/j.jdin.2024.03.013_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bjd.15324","article-title":"Cutaneous squamous cell carcinoma: an epidemiological review","volume":"177","author":"Green","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2024.03.013_bib32","first-page":"241","article-title":"The use of topical imiquimod for the treatment of actinic keratosis: a status report","volume":"76","author":"Del Rosso","year":"2005","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.jdin.2024.03.013_bib33","first-page":"433","article-title":"5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction","volume":"33","author":"Gross","year":"2007","journal-title":"Dermatol Surg"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T03:59:23Z","timestamp":1740887963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328724000518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":29,"alternative-id":["S2666328724000518"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2024.03.013","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International time trends and differences in topical actinic keratosis therapy utilization","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2024.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}